Brian J. Long - Concepedia

Author

Brian J. Long

University of Maryland, Baltimore ORCID

Also Known As

B J Long, B Long, B. J. Long, B. Long, B.J Long, BRIAN J. LONG, Baichao Long, Brian J Long, Brian J. Long, Brian Long

131

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

University of Maryland, Baltimore Merck & Co., Inc., Rahway, NJ, USA (United States)University of North Carolina at Chapel Hill U-M Rogel Cancer Center The University of Texas MD Anderson Cancer Center

About

Brian J. Long is an author at University of Maryland, Baltimore specializing in medicine, pharmacology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	31	3.2K
2	Biochemistry	12	12	930
3	Natural Sciences	3	3	171
4	Public Health	2	2	91
5	Health Sciences	1	1	673

Brian J. Long

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors Erick J. Morris, Sharda Jha, Clifford R. Restaino, Cancer Discovery PharmacotherapyTumor BiologyDrug ResistanceMek InhibitorsReceptor Tyrosine Kinase	2013	673
An orally available non-nucleotide STING agonist with antitumor activity Bo‐Sheng Pan, Samanthi A. Perera, Jennifer Piesvaux, Science Antitumor ActivityImmunologyImmunoeditingImmunologic MechanismPharmacotherapy	2020	609
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression Tikvah K. Hayes, Nicole F. Neel, Chaoxin Hu, Cancer Cell OncologyPancreatic CancerLong-term Erk InhibitionMedicineSenescence-like Growth Suppression	2015	271
Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy Amy D. Guertin, Jing Li, Yaping Liu, Molecular Cancer Therapeutics	2013	169
Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Apinya Thiantanawat, Brian J. Long, Angela Brodie PubMed Aromatase InhibitorsBreast OncologyOncologyAntiestrogen TamoxifenBiochemistry	2003	162
The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling Andrea Basso, Asra Mirza, Gongjie Liu, Journal of Biological Chemistry	2005	161
Aromatase and COX-2 expression in human breast cancers A. Brodie, Qing Lü, Brian J. Long, The Journal of Steroid Biochemistry and Molecular Biology Breast OncologyBiochemistryMedicineAromataseBreast Cancer	2001	149
Activation of Mitogen-Activated Protein Kinase in Xenografts and Cells during Prolonged Treatment with Aromatase Inhibitor Letrozole Danijela Jelovac, Gauri Sabnis, Brian J. Long, Cancer Research	2005	146
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors Stergios J. Moschos, Ryan J. Sullivan, Wen-Jen Hwu, JCI Insight	2018	145
Therapeutic Strategies Using the Aromatase Inhibitor Letrozole and Tamoxifen in a Breast Cancer Model Brian J. Long, Danijela Jelovac, Venkatesh Handratta, JNCI Journal of the National Cancer Institute	2004	136

Page 1